Skip to main content

Table 2 Germ-line variants and clinicopathologic characteristics of breast cancer patients by study

From: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

   ABCS
N = 1076
HABCS
N = 152
HEBCS
N = 599
SEARCH
N = 1922
P value*
   N % N % N % N %  
MDM2 SNP309 TT 444 41.3 55 36.2 183 30.6 774 40.3  
  GT 487 45.3 73 48.0 311 51.9 913 47.5  
  GG 145 13.5 24 15.8 105 17.5 235 12.2 < 0.001
TP53 R72P GG 570 53.0 85 55.9 314 52.4 1052 54.7  
  GC 422 39.2 55 36.2 236 39.4 733 38.1  
  CC 84 7.8 12 7.9 49 8.2 137 7.1 0.9
Stage 1 341 31.9 83 69.2 205 36.9 861 52.4  
  2 581 54.4 36 30.0 295 53.1 713 43.4  
  3 146 13.7 1 0.8 56 10.1 69 4.2 < 0.001
  Missing 8   32   43   279   
Differentiation grade 1 338 35.8 9 8.7 138 24.6 368 25.4  
  2 317 33.6 55 53.4 243 43.2 647 44.7  
  3 288 30.5 39 37.9 181 32.2 431 29.8 < 0.001
  Missing 133   49   37   476   
ER status tumor Negative 240 34.2 18 15.4 135 23.2 175 19.8  
  Positive 461 65.8 99 84.6 446 76.8 708 80.2 < 0.001
  Missing 375   35   18   1039   
p53 status tumor Negative 473 70.4    335 76.7    
  Positive 199 29.6    102 23.3    0.02
  Missing 404   152   162   1922   
Vital status patient Alive 694 64.5 129 84.9 462 77.1 1596 83.0  
  Deceased, all 382 35.5 23 15.1 137 22.9 326 17.0 < 0.001
  Deceased, breast cancer 337   20   105     
Years of diagnosis Range 1974 to 1994   1997 to 2003   1997 to 1998   1991 to 1996   
Age at diagnosis Mean ± SD 42.8 5.2 56.8 11.3 56.4 12.8 50.1 7.7 < 0.001
Follow-up Mean ± SD 10.5 5.7 6.5 1.9 7.3 2.1 6.3 2.1 < 0.001
  1. * P value of comparison of either categories of non-missing data among studies (by chi-square) or comparison of continuous data (by t-test).